Scholarlink

Purpose <p>To characterize temporal trends in clinicopathological features, therapeutic approaches, and survival outcomes of patients with ipsilateral breast tumor recurrence (IBTR).</p> Methods <p>A population-based retrospective cohort study (2010–2021) was conducted using the Surveillance, Epidemiology, and End Results (SEER) database. Primary endpoints focused on evaluating temporal trends in clinicopathological features and treatment modalities, while secondary endpoints were the assessment of 3-year overall survival (OS) and breast cancer-specific survival (BCSS). Temporal trends were analyzed using Joinpoint Regression (version 4.9.1.0).</p> Results <p>The cohort comprised 9,321 patients with IBTR. Most tumors were early stage (T1: 68.6%, 95% CI 67.6–69.6; N0:88.2%, 95%CI 87.5–88.6) with estrogen receptor-positive/HER2-negative (ER + /HER2-) predominance (72.8%, 95%CI:70.6–75.0), showing a significant annual increase (annual percentage change [APC] = 1.25%, <i>P</i> &lt; 0.001). The utilization of repeat breast-conserving surgery significantly increased post-2014 (APC = 5.19, P = 0.04). The utilization rate of radiotherapy was 10.5% (95%CI:9.4–11.6; P = 0.01), while chemotherapy use exhibited estrogen receptor (ER)-status-dependent variations. The 3-year OS and BCSS rates were 87.1% (95%CI:86.0–88.2) and 93.5% (95%CI:92.7–94.1), respectively, with significantly superior outcomes observed in patients aged &lt; 70&#xa0;years (<i>P</i> &lt; 0.001).</p> Conclusions <p>IBTR predominantly manifests as early stage, lymph node-negative, and ER + /HER2- disease. Treatment approaches for IBTR are evolving. However, the differences in survival outcomes observed among elderly patients indicate possible disparities in treatment based on age, which require further exploration.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Changes in Ipsilateral Breast Tumor Recurrence: Characteristics, Treatment, and Survival

  • 期刊论文

  • 发表日期：

    2026年2月25日

查看全文
  • Wei-Wen Li,
  • Qun-Chen Zhang,
  • Chun-Mei Chen,
  • Bo Xu,
  • Yong Li

摘要

Purpose

To characterize temporal trends in clinicopathological features, therapeutic approaches, and survival outcomes of patients with ipsilateral breast tumor recurrence (IBTR).

Methods

A population-based retrospective cohort study (2010–2021) was conducted using the Surveillance, Epidemiology, and End Results (SEER) database. Primary endpoints focused on evaluating temporal trends in clinicopathological features and treatment modalities, while secondary endpoints were the assessment of 3-year overall survival (OS) and breast cancer-specific survival (BCSS). Temporal trends were analyzed using Joinpoint Regression (version 4.9.1.0).

Results

The cohort comprised 9,321 patients with IBTR. Most tumors were early stage (T1: 68.6%, 95% CI 67.6–69.6; N0:88.2%, 95%CI 87.5–88.6) with estrogen receptor-positive/HER2-negative (ER + /HER2-) predominance (72.8%, 95%CI:70.6–75.0), showing a significant annual increase (annual percentage change [APC] = 1.25%, P < 0.001). The utilization of repeat breast-conserving surgery significantly increased post-2014 (APC = 5.19, P = 0.04). The utilization rate of radiotherapy was 10.5% (95%CI:9.4–11.6; P = 0.01), while chemotherapy use exhibited estrogen receptor (ER)-status-dependent variations. The 3-year OS and BCSS rates were 87.1% (95%CI:86.0–88.2) and 93.5% (95%CI:92.7–94.1), respectively, with significantly superior outcomes observed in patients aged < 70 years (P < 0.001).

Conclusions

IBTR predominantly manifests as early stage, lymph node-negative, and ER + /HER2- disease. Treatment approaches for IBTR are evolving. However, the differences in survival outcomes observed among elderly patients indicate possible disparities in treatment based on age, which require further exploration.